| Product NDC: | 55390-109 |
| Proprietary Name: | Clindamycin |
| Non Proprietary Name: | Clindamycin phosphate |
| Active Ingredient(s): | 150 mg/mL & nbsp; Clindamycin phosphate |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 55390-109 |
| Labeler Name: | Bedford Laboratories |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA065206 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20050404 |
| Package NDC: | 55390-109-01 |
| Package Description: | 1 VIAL in 1 BOX, UNIT-DOSE (55390-109-01) > 60 mL in 1 VIAL |
| NDC Code | 55390-109-01 |
| Proprietary Name | Clindamycin |
| Package Description | 1 VIAL in 1 BOX, UNIT-DOSE (55390-109-01) > 60 mL in 1 VIAL |
| Product NDC | 55390-109 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Clindamycin phosphate |
| Dosage Form Name | INJECTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20050404 |
| Marketing Category Name | ANDA |
| Labeler Name | Bedford Laboratories |
| Substance Name | CLINDAMYCIN PHOSPHATE |
| Strength Number | 150 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Decreased Sebaceous Gland Activity [PE],Lincosamide Antibacterial [EPC],Lincosamides [Chemical/Ingredient] |